Attitude and Execution Combine to be a Self-fulfilling Prophecy

16 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

An entrepreneur’s attitude and ability to execute the plan have an enormous impact on their overall success or failure. Life Science Nation (LSN) has created an ecosystem where entrepreneurs who are seeking capital or licensing deals can identify and match themselves up with partners that are precisely right for their stage of development and product.

Where LSN sees things break down is when entrepreneurs decide to pause their partnering efforts or skip the next partnering event because they are not getting the results they want. They fail to stick with the plan that fundraising is a pure numbers game, and it takes 9-18 months and hundreds of partnering meetings to find the few compelling partners that are a great fit and can lead to transactions. You need to buy off on a process for finding and meeting potential partners and work that process knowing it is always going to be a tough road.

What entrepreneurs forget is that it only takes one good connection, one good meeting, to turn the momentum around and change the dynamic of the partnering campaign and start to pick up momentum.

Entrepreneurs with a positive attitude and a relentless willingness to stick with the process will be more motivated to take risks and push themselves to go the extra mile. They must remain focused on their goals and be open to feedback and criticism and always move forward as a global partnering campaign ebbs and flows. None of this is news but at the end of the day persistence is what will make the difference and that is why LSN has 5 RESI events a year, with options for in-person, hybrid, and virtual, to provide an ecosystem that will allow the buyers and sellers to meet and get matched up, create a dialogue that can lead to a relationship and eventual transaction.

The Digital RESI, March 14-16 event is a fully virtual conference, and will offer 300+ investors and licensing partners, Innovation Pitch Challenge, Entrepreneurial Education, funding and partnering panels and workshops.  I submit that if you are a startup looking for global partners you must keep up the effort through digital and face2face events and not let chances slip by.

Hot Investor Mandate: CVC Arm of Global Pharma Invests Up to $15M Over the Company’s Lifecycle, Seeking Therapeutics & Digital Health Opportunities

16 Feb

A firm based invests strategically on behalf of a global pharmaceutical company. The firm will invest mostly in therapeutics, and a bit in digital health.

The firm is interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $15M over the life of an investment for therapeutics companies, and slightly less for digital health companies. The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments – the firm considers opportunities globally but focuses on Europe, Middle East and North America.

The firm is strategically mandated to invest in opportunities beyond the parent company’s core areas of business.  The fund seeks to invest in companies with therapeutic platform technologies and digital health. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology (esp. new therapeutic modalities, such as cell / gene therapy), regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology and immunomodulation), tissue regeneration (stem cells, NCEs, biologics), anti-infectives with novel MOA, and microbiome; within digital health, the firm is interested in patient care management (i.e. diagnosis and monitoring of disease, prevention of onset and progression of disease including digital biomarkers, population management), medication adherence, digital companion therapy, and digital therapy as stand alone. The firm will also consider opportunities in other indication areas outside of the aforementioned key areas of interest. The firm generally invests in preclinical assets.

The firm invests in technologies of strategic importance the parent company. The firm only invests in privately held companies.  The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe-Based VC Seeks Therapeutics Companies in Pre-Clinical and Early Clinical Stage, Also Active in Company Building

16 Feb

A venture capital firm with offices in Western Europe current invests from their third fund which focuses on investments in Europe based therapeutics and medical innovation. The firm invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics ventures. The firm is agnostic regarding technologies and indication areas and invests in companies with assets 12 months or less to the clinic, as well as assets in phase 1 or 2.  (i.e Series A and Series B)

Moreover, the firm is a company builder, identifying academic projects with potential for company creation. The company has developed a specific model of collaboration between the academic, the firm and an industrial to create companies.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Investment Firm Provides Funding to Global Opportunities in the Intersection of Science, Technology, Data Science, etc.

16 Feb

A venture capital firm based in the US invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.

The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, and is not interested in traditional medical devices or digital health.

The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Investment Firm Invests Up to $10M in USA or Europe-Based Companies Across All Life Science Sectors, Typically Investing at Seed Stage

16 Feb

A private investment office is actively involved in the management of a diverse portfolio of investments in private equity and venture capital.

The firm accelerates commercialization of ground-breaking innovation through investments, experienced hands-on management and the intelligent use of partnering. The firm focuses on a number of areas around which it has build teams of senior execs, world leading experts and advisors drawn from industry, finance, academia and regulatory bodies to support and accelerate its ventures.

In Life Sciences, the firm typically invests at seed stage or before a company has been formed and develop these early opportunities through preclinical phase; at late preclinical/early clinical stage the firm gets co-investors involved. The firm prefers areas where there are multiple capital efficient routes to market, with opportunities for early proof of concept or early out-licensing or exits.

Currently, the firm manages a $150M fund and makes investments from $100K to $10M, depending on the opportunity. The firm is seeking a couple of opportunities to add to its portfolio. The firm invests in companies based in the USA and/or Europe.

The firm is sector- and stage- agnostic. In terms of biotech indications, the firm has invested in anti-infectives and particularly antimicrobial resistance, as well as immuno-modulatory anti-inflammatory indications and orphan and rare diseases.

The firm looks for a strong management team with proven track-record and a ground-breaking technology addressing an unmet need. The firm seeks to take significant stakes and board seats. In addition, the firm may provide active support leveraging its network of senior execs, experts and advisors to accelerate the development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Early Bird Ends Tomorrow – Meet With These Investors at Digital RESI March

9 Feb

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Life Science Nation’s next conference, Digital RESI March, is coming up in just over a month. We are excited to continue facilitating meaningful connections between early-stage life science companies and investors/strategic partners through this 3-day virtual conference, which will include a robust agenda of investor panels, workshops (including a new educational track), and the Innovator’s Pitch Challenge (IPC), through which we will have life science companies present live pitches in front of a judging panel.

We expect 300+ investors to join the upcoming event. With a 24-hour meeting capacity, attendees will be able to join the conference at the comfort of their home and schedule meetings based on their availability, regardless of what time zone they are in.

Below is a selected list of participating investors that you can expect to meet at Digital RESI March. If you are actively fundraising and looking to get in front of more investors, make sure to register by tomorrow to save $200 on your registration!

Partial List of Digital RESI March Confirmed Investors

As Feb. 8, 2023

CI-02092023

register-now-button

Digital RESI March 2023 Email Banner.(NEWtouse)

Entrepreneurial Education at Digital RESI March

9 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Digital RESI March will feature a novel entrepreneurial education track, the LSN Global Partnering Campaign and Roadshow Preparation course, which will include six classes total, two classes that will be delivered each day of the 3-day virtual event. This education focus will be for entrepreneurs who are starting to plan for their fundraising and licensing partner search and how LSN can help. An important theme of the education will concern how to plan and execute a global roadshow efficiently, which can greatly determine an early-stage entity’s success when moving from their regional environment to the global competitive landscape. The education sessions are highlighted below:

RESI-March-Agenda-n

Participating in the classes will allow the attendees to hear firsthand from LSN Founder and CEO, Dennis Ford, on issues including the importance of getting your company story straight, cogently weaving this narrative through multiple modalities (tagline to pitch deck), and how to avoid some of the most common pitfalls that catch first-time CEOs off-guard. Throughout the sessions on Wednesday (3/15) and Thursday (3/16), participants will hear from members of LSN’s Business Development and Investor Research teams on how to develop a professional set of marketing collateral, what the 10 myths of fundraising are, and strategies to boost partnering success in the global arena.

Attendees of RESI will be able to access the educational content in two methods: either through 1-day and 3-day partnering registrations ($695 and $995 respectively) which include the ability to book meetings with the capital investors and licensing partners who are attending Digital RESI March, or through the Audience Access Pass ($295) which grants full access to all of the education content & panels at Digital RESI March, but with no partnering.

register-now-button

Digital RESI March 2023 Email Banner.(NEWtouse)

← Older Entries
Newer Entries →